newsfilter
← Latest News
GlobeNewswire·

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data demonstrated